SG Americas Securities LLC Trims Position in Solventum Co. (NYSE:SOLV)

SG Americas Securities LLC reduced its position in Solventum Co. (NYSE:SOLV) by 24.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 19,183 shares of the company’s stock after selling 6,100 shares during the period. SG Americas Securities LLC’s holdings in Solventum were worth $1,267,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of SOLV. Trian Fund Management L.P. grew its position in shares of Solventum by 32.9% in the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after purchasing an additional 1,765,676 shares during the period. State Street Corp increased its stake in shares of Solventum by 3.1% during the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after acquiring an additional 185,938 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Solventum by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock worth $232,608,000 after acquiring an additional 128,317 shares during the period. Hotchkis & Wiley Capital Management LLC acquired a new stake in shares of Solventum in the third quarter worth approximately $125,488,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Solventum by 0.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,053,771 shares of the company’s stock valued at $73,469,000 after purchasing an additional 3,745 shares during the period.

Solventum Trading Up 0.1 %

Shares of NYSE SOLV opened at $75.06 on Tuesday. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The firm’s 50-day moving average price is $69.56 and its two-hundred day moving average price is $66.56.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, November 7th. The company reported $1.15 earnings per share for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.23). The company had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.05 billion. On average, research analysts predict that Solventum Co. will post 6.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Morgan Stanley increased their price target on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Stifel Nicolaus began coverage on Solventum in a report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price on the stock. Mizuho initiated coverage on Solventum in a research note on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price target for the company. Finally, Piper Sandler lifted their price objective on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, Solventum presently has an average rating of “Hold” and an average price target of $68.29.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.